Evaluation of efficacy and safety of rucinol serum in patients with melasma: A randomized controlled trial

British Journal of Dermatology

Volumn 156, Issue 5, 2007, Pages 997-1004

  Khemis, A ^a   Kaiafa, A ^a   Queille Roussel, C ^a   Duteil, L ^a   Ortonne, J P ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

Melasma; Randomized controlled trial; Rucinol serum; Split face design; Vehicle controlled comparison

Indexed keywords

RESORCINOL DERIVATIVE; RUCINOL SERUM; SUNSCREEN; UNCLASSIFIED DRUG;

ADULT; APPLICATION SITE BURNING; APPLICATION SITE DESQUAMATION; APPLICATION SITE DRYNESS; APPLICATION SITE ERYTHEMA; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; ARTICLE; CHLOASMA; CLINICAL ARTICLE; CLINICAL TRIAL; COLORIMETRY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FACE; FEMALE; HUMAN; MEDICAL PHOTOGRAPHY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SKIN ABRASION; SKIN COLOR; SKIN PIGMENTATION; SKIN REDNESS;

ADMINISTRATION, TOPICAL; ADULT; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ITALY; MELANOSIS; MIDDLE AGED; PROSPECTIVE STUDIES; RESORCINOLS; SKIN PIGMENTATION; TREATMENT OUTCOME;

EID: 34247325607     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.07814.x     Document Type: Article

References (12)

1. Jimbow K, Minamitsuji Y. Topical therapies for melasma and disorders of hyperpigmentation. Dermatol Ther 2001 14 : 35 45.
2. Balkrishnan R, McMichael AJ, Hu JY et al. Correlates of health-related quality of life in women with severe facial blemishes. Int J Dermatol 2006 45 : 111 15.
3. Balkrishnan R, Kelly AP, Torok H. Improved quality of life with effective treatment of facial melasma: the pigment trial. J Drugs Dermatol 2004 3 : 377 1.
4. Halder RM, Richards GM. Management of dyschromias in ethnic skin. Dermatol Ther 2004 17 : 151 7.
5. Levin CY, Maibach H. Exogenous ochronosis. An update on clinical features, causative agents and treatment options. Am J Clin Dermatol 2001 2 : 213 17.
6. Kimbrough-Green CK, Griffiths CE, Finkel LJ et al. Topical retinoic acid (tretinoin) for melasma in black patients. A vehicle-controlled clinical trial. Arch Dermatol 1994 130 : 727 33.
7. Katagiri T, Okubo M, Oyobikawa K et al. Novel melanogenic enzymes for controlling hyperpigmentation. 20th IFSCC International Congress 1998 39 : 1 11.
8. Akasaka T, Ohurazaka H, Nishioheda G et al. Topically applied 0.3% 4-n-butylresorcinol decreases pigmentation after laser therapy. Environ Derm 2002 9 : 11 15.
9. Researching Committee of Rucinol®. The study on the efficacy of Rucinol® (4-n-butylresorcinol) in chloasma. Nishinihon J Dermatol 1999 61 : 813 19.
10. Merck Médication Familiale. Data on file: Evic France, January 2002.
11. Haddad AL, Matos LF, Brunstein F et al. A clinical, prospective, randomized, double-blind trial comparing skin whitening complex with hydroquinone vs. placebo in the treatment of melasma. Int J Dermatol 2003 42 : 153 6.
12. Ennes SBP, Paschoalick RC, Mota de Avelar Alchorne M. A double-blind, comparative, placebo-controlled study of the efficacy and tolerability of 4% hydroquinone as a depigmenting agent in melasma. J Dermatol Treat 2000 11 : 173 9.